629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Autor: Jameel Muzaffar, Tae Min Kim, Julie Brahmer, Dirk G Brockstedt, Chia-Chi Lin, Michael Chisamore, Ki Hyeong Lee, Paul D Kassner, Nuttapong Ngamphaiboon, William Ho, Nicole Nasrah, Pratibha Desai, Yin-Hsun Feng, Shang-Yin Wu, Rakesh Kumar Goyal
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Druh dokumentu: article
ISSN: 2051-1426
DOI: 10.1136/jitc-2023-SITC2023.0629-C
Databáze: Directory of Open Access Journals